Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

19%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
13(81.3%)
Phase 3
3(18.8%)
16Total
Phase 1(13)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT06206733Phase 3Active Not Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Role: collaborator

NCT05867420Phase 1Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Role: collaborator

NCT05306132Phase 1Recruiting

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

Role: lead

NCT04632108Phase 1Active Not Recruiting

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT05632939Phase 1Active Not Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Role: collaborator

NCT07109531Phase 3Not Yet Recruiting

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Role: lead

NCT06614608Phase 1Not Yet Recruiting

The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

Role: lead

NCT04143607Phase 3Active Not Recruiting

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Role: lead

NCT05509985Phase 1Unknown

A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

Role: collaborator

NCT05554666Phase 1Unknown

A Study of ASKG315 in Patients With Advanced Solid Tumors.

Role: collaborator

NCT05631678Phase 1Completed

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Role: lead

NCT03502850Phase 1Unknown

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Role: lead

NCT04360915Phase 1Completed

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

Role: lead

NCT03120273Phase 1Unknown

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults(Part 2)

Role: collaborator

NCT03115762Phase 1Unknown

Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects

Role: lead

NCT03011125Phase 1Completed

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)

Role: collaborator

All 16 trials loaded